What is LeMaitre Vascular Inc?
develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific.
LMAT · Verdict
Solid reward · moderate risk
LMAT stands out on cash flow and profitability, but watch the valuation signal.
Based on 88% data coverage
LMAT · Verdict
15% free-cash-flow margin
23% net margin · 15% ROE
Rev +15.6% CAGR · earnings +40.9%
Above average
P/E 34.8× · PEG 2.05
Model-based scoring. For information only — not financial advice.
develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.07B, and a P/E ratio of 39.1x.
The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.